Last reviewed 2026-04-20 · How we verify

Levotensin (LEVOMOPROLOL)

Phase 2 active Small molecule

Levotensin (generic name: LEVOMOPROLOL) is a levomoprolol drug. It is currently in Phase 2 development.

Levotensin works by interacting with the body's adrenergic receptors.

Levotensin, also known as levomoprolol, is a small molecule drug in the levomoprolol class. Its exact target and mechanism of action are unknown, but it is believed to work by interacting with the body's adrenergic receptors. Levotensin is not FDA-approved for any indications, and its commercial status, including patent status and generic availability, is unclear. Further research is needed to determine its safety and efficacy. As a result, levotensin is not currently available for clinical use.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	LEVOMOPROLOL
Drug class	levomoprolol
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Think of adrenergic receptors like locks on a door. Levotensin is a key that fits into these locks, which can help slow down the heart rate and reduce blood pressure. This can be helpful for people with certain heart conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Levotensin CI brief — competitive landscape report
Levotensin updates RSS · CI watch RSS

Frequently asked questions about Levotensin

What is Levotensin?

Levotensin (LEVOMOPROLOL) is a levomoprolol drug.

How does Levotensin work?

Levotensin works by interacting with the body's adrenergic receptors.

What is the generic name of Levotensin?

LEVOMOPROLOL is the generic (nonproprietary) name of Levotensin.

What drug class is Levotensin in?

Levotensin belongs to the levomoprolol class. See all levomoprolol drugs at /class/levomoprolol.

What development phase is Levotensin in?

Levotensin is in Phase 2.

Drug class: All levomoprolol drugs
Therapeutic area: All drugs in Cardiovascular

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing